Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Azarga 10 mg/ml + 5 mg/ml eye drops, suspension
Medicines register · Ireland

Azarga 10 mg/ml + 5 mg/ml eye drops, suspension

Authorisation EU/1/08/482/1-2 · Novartis Europharm Limited

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 21 Nov 2026
Licence holder
Novartis Europharm Limited (all products →)
Active substances
Timolol Maleate, Brinzolamide
Dosage form
Eye drops, suspension
Route of administration
Ocular use
ATC codes
S01ED, S01ED51
First authorised
25/11/2008
Prescription status
Product subject to prescription which may be renewed (B)
Supply
Supply through pharmacies only
Legal basis
New active substance (Article 8(3) of Directive No 2001/83/EC)

Timolol Maleate: supply and approvals

23 authorised products on the HPRA list contain Timolol Maleate. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 20 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 20 Nov 2026)
Germany (BfArM)
4 supply notices, e.g. Timolol Micro Labs 5 mg/ml Augentropfen, Lösung (13 Oct 2026 to 27 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

Brinzolamide: supply and approvals

6 authorised products on the HPRA list contain Brinzolamide. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 20 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 20 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 20 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 482. It has been authorised for 17 years (since 25 November 2008). The HPRA list does not say whether it is on sale.

Open the European Commission’s Union Register record →

Other medicines with Timolol Maleate in Ireland

11 other products on the HPRA list contain Timolol Maleate, from 8 licence holders; 4 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
COSOPT 20mg/ml + 5mg/ml eye drops, solutionSanten OYNational authorisation (PA)Marketed
Latanoprost/Timolol Zentiva 50 microgram/ml + 5 mg/ml eye drops solutionZentiva k.s.National authorisation (PA)Marketed
Tidimaz 20 mg/ml + 5 mg/ml eye drops, solutionFarmaprojects S.A.UNational authorisation (PA)Marketed
Timofluid 1 mg/g eye gel in single-dose containerLaboratoires TheaNational authorisation (PA)Marketed
Bitifrin 0.3 mg/ml + 5 mg/ml eye drops, solutionFarmaprojects S.A.UNational authorisation (PA)Not marketed
Combigan 2 mg/ml + 5 mg/ml eye drops, solutionAbbVie LimitedNational authorisation (PA)Not marketed
Dorzolamide/Timolol Brown & Burk 20 mg/ml + 5 mg/ml eye drops, solution in single-dose containerBrown & Burk IR LimitedNational authorisation (PA)Not marketed
Duelym 0.1 mg/g + 1 mg/g eye gel in single dose containerLaboratoires TheaNational authorisation (PA)Not marketed
Duotrav (Extravan) 40 micrograms/mL + 5 mg/mL eye drops, solutionNovartis Europharm LimitedCentralised EU authorisationNot stated
Eyzeetan 0.3 mg/ml + 5 mg/ml eye drops, solutionAspire Pharma (Malta) LimitedNational authorisation (PA)Not marketed
Loracom 50 microgram/ml + 5 mg/ml eye drops, solutionFarmaprojects S.A.UNational authorisation (PA)Not marketed

Other medicines with Brinzolamide in Ireland

5 other products on the HPRA list contain Brinzolamide, from 3 licence holders; 1 of them is marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Brinzolamide 10 mg/ml eye drops, SuspensionAccord Healthcare Ireland Ltd.National authorisation (PA)Marketed
Azopt 10 mg/ml eye drops, suspensionNovartis Europharm LimitedCentralised EU authorisationNot stated
Azopt 10 mg/ml eye drops, suspensionNovartis Europharm LimitedCentralised EU authorisationNot stated
Brinzolamide Rowex 10 mg/ml eye drops, suspensionRowex Limited,National authorisation (PA)Not marketed
SIMBRINZA 10 mg/mL + 2 mg/mL eye drops, suspensionNovartis Europharm LimitedCentralised EU authorisationNot stated

Other substances in ATC group S01ED

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 8 other active substances share the group S01ED with this product:

Timolol (8) · Latanoprost (3) · Tafluprost (2) · Brimonidine tartrate (1) · Dorzolamide (1) · Dorzolamide hydrochloride (1) · Travopost (1) · Bimatoprost (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Novartis Europharm Limited holds 178 products on the HPRA list, with 65 different active substances; 0 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.